√ Registration information
No. | Content |
|
|
Executive summary |
|
|
Methodology and scope |
|
1 | Profiles of coming off-patent herbicides |
|
1.1 | Aminopyralid |
|
1.2 | Pyrasulfotole |
|
1.3 | Pyroxasulfone |
|
1.4 | Pyroxsulam |
|
1.5 | Saflufenacil |
|
1.6 | Indaziflam |
|
1.7 | Cyprosulfamide |
|
2 | Profiles of coming off-patent insecticides |
|
2.1 | Chlorantraniliprole |
|
2.2 | Cyantraniliprole |
|
2.3 | Cyclaniliprole |
|
2.4 | Spirotetramat |
|
3 | Profiles of coming off-patent fungicides |
|
3.1 | Mandipropamid |
|
3.2 | Penflufen |
|
3.3 | Bixafen |
|
3.4 | Fluopyram |
|
3.5 | Isopyrazam |
|
3.6 | Sedaxane |
Table No. | Table Title |
Table 1.1-1 | Patent information of aminopyralid in some countries/regions, as of July 2021 |
Table 1.1-2 | Registration information of aminopyralid in Argentina, as of July 2021 |
Table 1.1-3 | Registration information of aminopyralid in Australia, as of July 2021 |
Table 1.1-4 | Registration information of aminopyralid in Belgium, as of July 2021 |
Table 1.1-5 | Registration information of aminopyralid in Brazil, as of July 2021 |
Table 1.1-6 | Registration information of aminopyralid in Canada, as of July 2021 |
Table 1.1-7 | Registration information of aminopyralid in China, as of July 2021 |
Table 1.1-8 | Registration information of aminopyralid in Denmark, as of July 2021 |
Table 1.1-9 | Registration information of aminopyralid in Finland, as of July 2021 |
Table 1.1-10 | Registration information of aminopyralid in France, as of July 2021 |
Table 1.1-11 | Registration information of aminopyralid in Greece, as of July 2021 |
Table 1.1-12 | Registration information of aminopyralid in the Netherlands, as of July 2021 |
Table 1.1-13 | Registration information of aminopyralid in South Africa, as of April 2019 |
Table 1.1-14 | Registration information of aminopyralid in Switzerland, as of July 2021 |
Table 1.1-15 | Registration information of aminopyralid in the UK, as of July 2021 |
Table 1.1-16 | Registration information of aminopyralid in Uruguay, as of July 2021 |
Table 1.1-17 | Registration information of aminopyralid in the US, as of July 2021 |
Table 1.2-1 | Patent information of pyrasulfotole in some countries/regions, as of July 2021 |
Table 1.2-2 | Registration information of pyrasulfotole in Australia, as of July 2021 |
Table 1.2-3 | Registration information of pyrasulfotole in Canada, as of July 2021 |
Table 1.2-4 | Registration information of pyrasulfotole in South Africa, as of April 2019 |
Table 1.2-5 | Registration information of pyrasulfotole in the US, as of July 2021 |
Table 1.3-1 | Patent information of pyroxasulfone in some countries/regions, as of July 2021 |
Table 1.3-2 | Registration information of pyroxasulfone in Argentina, as of July 2021 |
Table 1.3-3 | Registration information of pyroxasulfone in Australia, as of July 2021 |
Table 1.3-4 | Registration information of pyroxasulfone in Brazil, as of July 2021 |
Table 1.3-5 | Registration information of pyroxasulfone in Canada, as of July 2021 |
Table 1.3-6 | Registration information of pyroxasulfone in China, as of July 2021 |
Table 1.3-7 | Registration information of pyroxasulfone in South Africa, as of April 2019 |
Table 1.4-1 | Patent information of pyroxsulam in some countries/regions, as of July 2021 |
Table 1.4-2 | Registration information of pyroxsulam in Australia, as of July 2021 |
Table 1.4-3 | Registration information of pyroxsulam in Belgium, as of July 2021 |
Table 1.4-4 | Registration information of pyroxsulam in Brazil, as of July 2021 |
Table 1.4-5 | Registration information of pyroxsulam in Canada, as of July 2021 |
Table 1.4-6 | Registration information of pyroxsulam in China, as of July 2021 |
Table 1.4-7 | Registration information of pyroxsulam in Denmark, as of July 2021 |
Table 1.4-8 | Registration information of pyroxsulam in France, as of July 2021 |
Table 1.4-9 | Registration information of pyroxsulam in Greece, as of July 2021 |
Table 1.4-10 | Registration information of pyroxsulam in the Netherlands, as of July 2021 |
Table 1.4-11 | Registration information of pyroxsulam in South Africa, as of April 2019 |
Table 1.4-12 | Registration information of pyroxsulam in Switzerland, as of July 2021 |
Table 1.4-13 | Registration information of pyroxsulam in the UK, as of July 2021 |
Table 1.4-14 | Registration information of pyroxsulam in the US, as of July 2021 |
Table 1.5-1 | Patent information of saflufenacil in some countries/regions, as of July 2021 |
Table 1.5-2 | Registration information of saflufenacil in Argentina, as of July 2021 |
Table 1.5-3 | Registration information of saflufenacil in Australia, as of July 2021 |
Table 1.5-4 | Registration information of saflufenacil in Brazil, as of July 2021 |
Table 1.5-5 | Registration information of saflufenacil in Canada, as of July 2021 |
Table 1.5-6 | Registration information of saflufenacil in Chile, as of July 2021 |
Table 1.5-7 | Registration information of saflufenacil in China, as of July 2021 |
Table 1.5-8 | Registration information of saflufenacil in South Africa, as of April 2019 |
Table 1.5-9 | Registration information of saflufenacil in Uruguay, as of July 2021 |
Table 1.6-1 | Patent information of indaziflam in some countries/regions, as of July 2021 |
Table 1.6-2 | Registration information of indaziflam in Argentina, as of July 2021 |
Table 1.6-3 | Registration information of indaziflam in Australia, as of July 2021 |
Table 1.6-4 | Registration information of indaziflam in Brazil, as of July 2021 |
Table 1.6-5 | Registration information of indaziflam in Canada, as of July 2021 |
Table 1.6-6 | Registration information of indaziflam in Chile, as of July 2021 |
Table 1.6-7 | Registration information of indaziflam in South Africa, as of April 2019 |
Table 1.6-8 | Registration information of indaziflam in Uruguay, as of July 2021 |
Table 1.6-9 | Registration information of indaziflam in the US, as of July 2021 |
Table 1.7-1 | Patent information of cyprosulfamide in some countries/regions, as of July 2021 |
Table 1.7-2 | Registration information of cyprosulfamide in Argentina, as of July 2021 |
Table 1.7-3 | Registration information of cyprosulfamide in Belgium, as of July 2021 |
Table 1.7-4 | Registration information of cyprosulfamide in Canada, as of July 2021 |
Table 1.7-5 | Registration information of Cyprosulfamide in Chile, as of July 2021 |
Table 1.7-6 | Registration information of cyprosulfamide in France, as of July 2021 |
Table 1.7-7 | Registration information of cyprosulfamide in Greece, as of July 2021 |
Table 1.7-8 | Registration information of cyprosulfamide in the Netherlands, as of July 2021 |
Table 2.1-1 | Patent information of chlorantraniliprole in some countries/regions, as of July 2021 |
Table 2.1-2 | Registration information of chlorantraniliprole in Australia, as of July 2021 |
Table 2.1-3 | Registration information of chlorantraniliprole in Canada, as of July 2021 |
Table 2.1-4 | Registration information of chlorantraniliprole in China, as of July 2021 |
Table 2.1-5 | Registration information of Chlorantraniliprole in Finland, as of July 2021 |
Table 2.1-6 | Registration information of chlorantraniliprole in France, as of July 2021 |
Table 2.1-7 | Registration information of chlorantraniliprole in Greece, as of July 2021 |
Table 2.1-8 | Registration information of chlorantraniliprole in the Netherlands, as of July 2021 |
Table 2.1-9 | Registration information of chlorantraniliprole in South Africa, as of April 2019 |
Table 2.1-10 | Registration information of chlorantraniliprole in Switzerland, as of July 2021 |
Table 2.1-11 | Registration information of chlorantraniliprole in the UK, as of July 2021 |
Table 2.1-12 | Registration information of chlorantraniliprole in Uruguay, as of July 2021 |
Table 2.1-13 | Registration information of chlorantraniliprole in the US, as of July 2021 |
Table 2.2-1 | Patent information of cyantraniliprole in some countries/regions, as of July 2021 |
Table 2.2-2 | Registration information of cyantraniliprole in Argentina, as of July 2021 |
Table 2.2-3 | Registration information of cyantraniliprole in Australia, as of July 2021 |
Table 2.2-4 | Registration information of cyantraniliprole in Belgium, as of July 2021 |
Table 2.2-5 | Registration information of cyantraniliprole in Canada, as of July 2021 |
Table 2.2-6 | Registration information of cyantraniliprole in China, as of July 2021 |
Table 2.2-7 | Registration information of cyantraniliprole in Finland, as of July 2021 |
Table 2.2-8 | Registration information of cyantraniliprole in France, as of July 2021 |
Table 2.2-9 | Registration information of cyantraniliprole in Greece, as of July 2021 |
Table 2.2-10 | Registration information of cyantraniliprole in the Netherlands, as of July 2021 |
Table 2.2-11 | Registration information of cyantraniliprole in South Africa, as of April 2019 |
Table 2.2-12 | Registration information of cyantraniliprole in the UK, as of July 2021 |
Table 2.2-13 | Registration information of cyantraniliprole in Uruguay, as of July 2021 |
Table 2.2-14 | Registration information of cyantraniliprole in the US, as of July 2021 |
Table 2.3-1 | Patent information of cyclaniliprole in some countries/regions, as of July 2021 |
Table 2.3-2 | Registration information of cyclaniliprolen in Australia, as of July 2021 |
Table 2.3-3 | Registration information of cyclaniliprole in Canada, as of July 2021 |
Table 2.3-4 | Registration information of cyclaniliprole in the US, as of July 2021 |
Table 2.4-1 | Patent information of spirotetramat in some countries/regions, as of July 2021 |
Table 2.4-2 | Registration information of spirotetramat in Australia, as of July 2021 |
Table 2.4-3 | Registration information of spirotetramat in Canada, as of July 2021 |
Table 2.4-4 | Registration information of Spirotetramat in Chile, as of July 2021 |
Table 2.4-5 | Registration information of spirotetramat in China, as of July 2021 |
Table 2.4-6 | Registration information of spirotetramat in Denmark, as of July 2021 |
Table 2.4-7 | Registration information of spirotetramat in France, as of July 2021 |
Table 2.4-8 | Registration information of spirotetramat in Greece, as of July 2021 |
Table 2.4-9 | Registration information of spirotetramat in the Netherlands, as of July 2021 |
Table 2.4-10 | Registration information of spirotetramat in the Switzerland, as of July 2021 |
Table 2.4-11 | Registration information of spirotetramat in the UK, as of July 2021 |
Table 2.4-12 | Registration information of spirotetramat in Uruguay, as of July 2021 |
Table 2.4-13 | Registration information of spirotetramat in the US, as of July 2021 |
Table 3.1-1 | Patent information of mandipropamid in some countries/regions, as of July 2021 |
Table 3.1-2 | Registration information of mandipropamid in Argentina, as of July 2021 |
Table 3.1-3 | Registration information of mandipropamid in Australia, as of July 2021 |
Table 3.1-4 | Registration information of mandipropamid in Belgium, as of July 2021 |
Table 3.1-5 | Registration information of mandipropamid in Brazil, as of July 2021 |
Table 3.1-6 | Registration information of mandipropamid in Canada, as of July 2021 |
Table 3.1-7 | Registration information of mandipropamid in Chile, as of July 2021 |
Table 3.1-8 | Registration information of mandipropamid in China, as of July 2021 |
Table 3.1-9 | Registration information of mandipropamid in Denmark, as of July 2021 |
Table 3.1-10 | Registration information of mandipropamid in Finland, as of July 2021 |
Table 3.1-11 | Registration information of mandipropamid in France, as of July 2021 |
Table 3.1-12 | Registration information of mandipropamid in Greece, as of July 2021 |
Table 3.1-13 | Registration information of mandipropamid in the Netherlands, as of July 2021 |
Table 3.1-14 | Registration information of mandipropamid in South Africa, as of April 2019 |
Table 3.1-15 | Registration information of mandipropamid in Switzerland, as of July 2021 |
Table 3.1-16 | Registration information of mandipropamid in the UK, as of July 2021 |
Table 3.1-17 | Registration information of mandipropamid in the US, as of July 2021 |
Table 3.2-1 | Patent information of penflufen in some countries/regions, as of July 2021 |
Table 3.2-2 | Registration information of penflufen in Australia, as of July 2021 |
Table 3.2-3 | Registration information of penflufen in Belgium, as of July 2021 |
Table 3.2-4 | Registration information of penflufen in Canada, as of July 2021 |
Table 3.2-5 | Registration information of penflufen in Chile, as of July 2021 |
Table 3.2-6 | Registration information of penflufen in China, as of July 2021 |
Table 3.2-7 | Registration information of penflufen in Finland, as of July 2021 |
Table 3.2-8 | Registration information of penflufen in the Netherlands, as of July 2021 |
Table 3.2-9 | Registration information of penflufen in the UK, as of July 2021 |
Table 3.2-10 | Registration information of penflufen in the US, as of July 2021 |
Table 3.3-1 | Patent information of bixafen in some countries/regions, as of July 2021 |
Table 3.3-2 | Registration information of bixafen in Argentina, as of July 2021 |
Table 3.3-3 | Registration information of bixafen in Australia, as of July 2021 |
Table 3.3-4 | Registration information of bixafen in Belgium, as of July 2021 |
Table 3.3-5 | Registration information of Bixafen in Canada, as of July 2021 |
Table 3.3-6 | Registration information of bixafen in Chile, as of July 2021 |
Table 3.3-7 | Registration information of bixafen in Denmark, as of July 2021 |
Table 3.3-8 | Registration information of bixafen in Finland, as of July 2021 |
Table 3.3-9 | Registration information of bixafen in France, as of July 2021 |
Table 3.3-10 | Registration information of bixafen in the Netherlands, as of July 2021 |
Table 3.3-11 | Registration information of bixafen in South Africa, as of April 2019 |
Table 3.3-12 | Registration information of bixafen in Switzerland, as of July 2021 |
Table 3.3-13 | Registration information of bixafen in the UK, as of July 2021 |
Table 3.3-14 | Registration information of bixafen in Uruguay, as of July 2021 |
Table 3.3-15 | Registration information of bixafen in the US, as of July 2021 |
Table 3.4-1 | Patent information of fluopyram in some countries/regions, as of July 2021 |
Table 3.4-2 | Registration information of fluopyram in Australia, as of July 2021 |
Table 3.4-3 | Registration information of fluopyram in Belgium, as of July 2021 |
Table 3.4-4 | Registration information of fluopyram in Brazil, as of July 2021 |
Table 3.4-5 | Registration information of fluopyram in Canada, as of July 2021 |
Table 3.4-6 | Registration information of fluopyram in China, as of July 2021 |
Table 3.4-7 | Registration information of fluopyram in Denmark, as of July 2021 |
Table 3.4-8 | Registration information of fluopyram in Finland, as of July 2021 |
Table 3.4-9 | Registration information of fluopyram in France, as of July 2021 |
Table 3.4-10 | Registration information of fluopyram in Greece, as of July 2021 |
Table 3.4-11 | Registration information of fluopyram in the Netherlands, as of July 2021 |
Table 3.4-12 | Registration information of fluopyram in South Africa, as of April 2019 |
Table 3.4-13 | Registration information of fluopyram in Switzerland, as of July 2021 |
Table 3.4-14 | Registration information of fluopyram in the UK, as of July 2021 |
Table 3.4-15 | Registration information of fluopyram in the US, as of July 2021 |
Table 3.5-1 | Patent information of isopyrazam in some countries/regions, as of July 2021 |
Table 3.5-2 | Registration information of isopyrazam in Argentina, as of July 2021 |
Table 3.5-3 | Registration information of isopyrazam in Australia, as of July 2021 |
Table 3.5-4 | Registration information of isopyrazam in Belgium, as of July 2021 |
Table 3.5-5 | Registration information of isopyrazam in China, as of July 2021 |
Table 3.5-6 | Registration information of isopyrazam in Finland, as of July 2021 |
Table 3.5-7 | Registration information of isopyrazam in France, as of July 2021 |
Table 3.5-8 | Registration information of isopyrazam in Greece, as of July 2021 |
Table 3.5-9 | Registration information of isopyrazam in the Netherlands, as of July 2021 |
Table 3.5-10 | Registration information of isopyrazam in the UK, as of July 2021 |
Table 3.5-11 | Registration information of isopyrazam in Uruguay, as of July 2021 |
Table 3.6-1 | Patent information of sedaxane in some countries/regions, as of July 2021 |
Table 3.6-2 | Registration information of sedaxane in Argentina, as of July 2021 |
Table 3.6-3 | Registration information of sedaxane in Australia, as of July 2021 |
Table 3.6-4 | Registration information of sedaxane in Canada, as of July 2021 |
Table 3.6-5 | Registration information of sedaxane in Chile, as of July 2021 |
Table 3.6-6 | Registration information of sedaxane in China, as of July 2021 |
Table 3.6-7 | Registration information of sedaxane in Denmark, as of July 2021 |
Table 3.6-8 | Registration information of sedaxane in Finland, as of July 2021 |
Table 3.6-9 | Registration information of sedaxane in France, as of July 2021 |
Table 3.6-10 | Registration information of sedaxane in Greece, as of July 2021 |
Table 3.6-11 | Registration information of sedaxane in the UK, as of July 2021 |
Table 3.6-12 | Registration information of sedaxane in Uruguay, as of July 2021 |
Table 3.6-13 | Registration information of sedaxane in the US, as of July 2021 |
Figure No. | Figure Title |
Figure 1.1-1 | Chemical structure of aminopyralid |
Figure 1.2-1 | Chemical structure of pyrasulfotole |
Figure 1.3-1 | Chemical structure of Pyroxasulfone |
Figure 1.4-1 | Chemical structure of pyroxsulam |
Figure 1.5-1 | Chemical structure of saflufenacil |
Figure 1.7-1 | Chemical structure of cyprosulfamide |
Figure 2.1-1 | Chemical structure of chlorantraniliprole |
Figure 2.2-1 | Chemical structure of cyantraniliprole |
Figure 2.3-1 | Chemical structure of cyclaniliprole |
Figure 2.3-2 | Route for synthesizing cyclaniliprole |
Figure 2.4-1 | Chemical structure of spirotetramat |
Figure 2.4-2 | Route for synthesizing spirotetramat |
Figure 3.1-1 | Chemical structure of mandipropamid |
Figure 3.2-1 | Chemical structure of penflufen |
Figure 3.3-1 | Chemical structure of bixafen |
Figure 3.4-1 | Chemical structure of fluopyram |
Figure 3.5-1 | Chemical structure of isopyrazam |
Figure 3.6-1 | Chemical structure of sedaxane |
Get the sample report of <Global Guide of Coming Off-patent Agrochemical Active Ingredients[Edition8]> now.
About CCM:
CCM is the leading market intelligence provider for China’s agriculture, chemicals, food & feed and life science markets. Founded in 2001, CCM offers a range of data and content solutions, from price and trade data to industry newsletters and customized market research reports. CCM is a brand of Kcomber Inc.
For more information about CCM, please visit www.cnchemicals.com or get in touch with us directly by emailing emarket1@cnchemicals.com or calling +86-20-37616606.